Login to Your Account

ASCO Frenzy in Full Bloom, OncoGenex's Ride Continues

By Randy Osborne

Monday, June 1, 2009
As the American Society of Clinical Oncology meeting kicked off Friday in Orlando, Fla., Wall Street and the scientific community - hardly short on cancer data in recent months - braced for an ASCO avalanche. News from the meeting was not expected to make the overall investment needle jump, at least in the view of Leerink Swann analyst John Sullivan, but individual companies are certain to benefit from favorable posters at the closely watched event.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription